Multischiume: Prevention of Pressure Ulcer on the Sacrum

Sponsor
Istituto Ortopedico Rizzoli (Other)
Overall Status
Completed
CT.gov ID
NCT03900455
Collaborator
(none)
711
9
2
4.9
79
16

Study Details

Study Description

Brief Summary

The aim of the present study was to assess whether the application of a multilayered dressing made of hydrocellular polyurethane foam conformed to the sacral area (MSP) in addition to standard preventive care reduces the rate of pressure ulcer (PU) and their severity in population at risk admitted in acute care Hospital.

Condition or Disease Intervention/Treatment Phase
  • Device: Hydrocellular polyurethane foam multilayer dressing
  • Procedure: Standard preventive care
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
711 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Effectiveness of the Use of a Polyurethane Foam Multilayer Dressing in the Sacral Area, in Addition to Standard Healthcare, to Prevent the Onset of Pressure Ulcer in Patients at Risk. Multicentric Randomized Controlled Trial
Actual Study Start Date :
Oct 21, 2019
Actual Primary Completion Date :
Mar 12, 2020
Actual Study Completion Date :
Mar 19, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Hydrocellular polyurethane foam multilayer dressing

Device: Hydrocellular polyurethane foam multilayer dressing
Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
Other Names:
  • ALLEVYN LIFE
  • Procedure: Standard preventive care
    Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score <17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure

    Active Comparator: standard preventive care

    Procedure: Standard preventive care
    Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score <17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure

    Outcome Measures

    Primary Outcome Measures

    1. Rate of any type of pressure ulcer in the sacral area. [On the seventh day of hospitalization or upon discharge from hospital, if that occurs before the seventh day]

      The ulcer will be classified according to the National Pressure Ulcers Advisory Panel Classification. Pressure ulcer are classified and described through the use of staging systems. Staging systems describe the extent of tissue loss and the physical appearance of the injury caused by pressure and/or shear. From stage 1 (intact skin) to Stage 4 (Full-thickness skin and tissue loss).

    Secondary Outcome Measures

    1. Pressure Ulcer Rate in the Sacral Area of Category≥ II [On the seventh day of hospitalization or upon discharge from hospital, if that occurs before the seventh day]

      The ulcer will be classified according to the National Pressure Ulcers Advisory Panel Classification. Pressure ulcer are classified and described through the use of staging systems. Staging systems describe the extent of tissue loss and the physical appearance of the injury caused by pressure and/or shear. From stage 1 (intact skin) to Stage 4 (Full-thickness skin and tissue loss).

    2. Skin irritation/damage due to the adhesive dressing [On the seventh day of hospitalization or upon discharge from hospital, if that occurs before the seventh day]

      Clinical evaluation. It refers to any sort of inflammation and/or discoloration that distorts the skin's normal appearance. The skin may become scaly, bumpy, itchy, or otherwise irritated.

    3. Number of dressing used per patient. [On the seventh day of hospitalization or upon discharge from hospital, if that occurs before the seventh day]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients at risk to develop Pressure Ulcer (Braden scale <17)

    • without sacrum Pressure Ulcer

    • Patients or legal guardians who give their consent to take part in the study

    Exclusion Criteria:
    • Patients with known allergy to the product being tested or dermatological diseases that prevent the use of topical products

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 ASO Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo Alessandria Italy 15121
    2 Ausl Bologna Ospedale Maggiore Bologna Italy 40133
    3 Policlinico di S.Orsola Azienda Ospedaliero-Universitaria di Bologna Bologna Italy 40138
    4 Ausl della Romagna Cesena Italy 47521
    5 Fondazione IRCCS Policlinico San Matteo Pavia Italy 27100
    6 Azienda USL- IRCCS di Reggio Emilia Reggio Emilia Italy 42122
    7 Policlinico Universitario Campus Bio-Medico di Roma Roma Italy 00128
    8 APSS Trento Trento Italy 38123
    9 Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy 37126

    Sponsors and Collaborators

    • Istituto Ortopedico Rizzoli

    Investigators

    None specified.

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Istituto Ortopedico Rizzoli
    ClinicalTrials.gov Identifier:
    NCT03900455
    Other Study ID Numbers:
    • Multischiume
    First Posted:
    Apr 3, 2019
    Last Update Posted:
    Feb 17, 2021
    Last Verified:
    Feb 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Istituto Ortopedico Rizzoli
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 17, 2021